Current Opinion in Cardiology最新文献_第9页

Salt restriction for treatment of hypertension - current state and future directions. 限盐治疗高血压--现状与未来方向。

IF 2.3 4区医学

Current Opinion in Cardiology Pub Date : 2023-11-02 DOI: 10.1097/hco.0000000000001098

Philip Nolan, John W McEvoy

引用次数: 0

Antithrombotic treatment following percutaneous coronary intervention in patients with high bleeding risk. 高出血风险患者经皮冠状动脉介入治疗后的抗凝治疗。

IF 2.3 4区医学

Current Opinion in Cardiology Pub Date : 2023-11-01 Epub Date: 2023-07-28 DOI: 10.1097/HCO.0000000000001075

Zaid I Almarzooq, Nora M Al-Roub, Scott Kinlay

{"title":"Antithrombotic treatment following percutaneous coronary intervention in patients with high bleeding risk.","authors":"Zaid I Almarzooq, Nora M Al-Roub, Scott Kinlay","doi":"10.1097/HCO.0000000000001075","DOIUrl":"10.1097/HCO.0000000000001075","url":null,"abstract":"Purpose of review: Review the clinical outcomes of different antithrombotic strategies in patients with high bleeding risk (HBR) after percutaneous coronary intervention (PCI).Recent findings: Patients with HBR after PCI include those with advanced age (e.g. >75 years of age), a prior history of major bleeding, anemia, chronic kidney disease, and those with indications for long-term anticoagulation. Strategies that successfully decrease bleeding risk in this population include shorter durations of dual antiplatelet therapy (DAPT; of 1-3 months) followed by single antiplatelet therapy with aspirin or a P2Y 12 inhibitor, or de-escalating from a more potent P2Y 12 inhibitor (prasugrel or ticagrelor) to less potent antiplatelet regimens (aspirin with clopidogrel or half-dose ticagrelor or half-dose prasugrel). Patients on DAPT, and a full dose anticoagulation for other indications, have a lower risk of major bleeding without an increase in 1-2-year adverse ischemic events, when rapidly switched from DAPT to a single antiplatelet therapy (within a week after PCI) with aspirin or clopidogrel. Longer term data on the benefits and risks of these strategies is lacking.Summary: In patients with HBR after PCI, shorter durations of DAPT (1-3 months) decrease the risk of major bleeding without increasing the risk of adverse ischemic events.","PeriodicalId":55197,"journal":{"name":"Current Opinion in Cardiology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10592282/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9889297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Coronary microvascular dysfunction and heart failure with preserved ejection fraction: what are the mechanistic links? 射血分数保留的冠状动脉微血管功能障碍和心力衰竭：机制联系是什么？

IF 2.3 4区医学

Current Opinion in Cardiology Pub Date : 2023-11-01 Epub Date: 2023-08-28 DOI: 10.1097/HCO.0000000000001082

Aish Sinha, Haseeb Rahman, Divaka Perera

{"title":"Coronary microvascular dysfunction and heart failure with preserved ejection fraction: what are the mechanistic links?","authors":"Aish Sinha, Haseeb Rahman, Divaka Perera","doi":"10.1097/HCO.0000000000001082","DOIUrl":"10.1097/HCO.0000000000001082","url":null,"abstract":"Purpose of review: Heart failure with preserved ejection fraction (HFpEF) accounts for half of all heart failure presentations and is associated with a dismal prognosis. HFpEF is an umbrella term that constitutes several distinct pathophysiological entities. Coronary microvascular dysfunction (CMD), defined as the inability of the coronary vasculature to augment blood flow adequately in the absence of epicardial coronary artery disease, is highly prevalent amongst the HFpEF population and likely represents one distinct HFpEF endotype, the CMD-HFpEF endotype. This review appraises recent studies that have demonstrated an association between CMD and HFpEF with an aim to understand the pathophysiological links between the two. This is of significant clinical relevance as better understanding of the pathophysiology underlying CMD-HFpEF may result in more targeted and efficacious therapeutic options in this patient cohort.Recent findings: There is a high prevalence of CMD, diagnosed invasively or noninvasively, in patients with HFpEF. Patients with HFpEF who have an impaired myocardial perfusion reserve (MPR) have a worse outcome than those with a normal MPR. Both MPR and coronary flow reserve (CFR) are associated with measures of left ventricular diastolic function and left ventricular filling pressures during exercise. Impaired lusitropy and subendocardial ischaemia link CMD and HFpEF mechanistically.Summary: CMD-HFpEF is a prevalent endotype of HFpEF and one that is associated with adverse cardiovascular prognosis. Whether CMD leads to HFpEF, through subendocardial ischaemia, or whether it is secondary to the impaired lusitropy that is characteristic of HFpEF is not known. Further mechanistic work is needed to answer this pertinent question.","PeriodicalId":55197,"journal":{"name":"Current Opinion in Cardiology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552827/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10508305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Introduction to the coronary artery surgery section. 冠状动脉外科简介。

IF 2.3 4区医学

Current Opinion in Cardiology Pub Date : 2023-11-01 Epub Date: 2023-10-05 DOI: 10.1097/HCO.0000000000001097

Marc Ruel, Robert Roberts

引用次数: 0

Impact of PCSK9 inhibitors on coronary atheroma phenotype following myocardial infarction: insights from intravascular imaging. PCSK9抑制剂对心肌梗死后冠状动脉粥样硬化表型的影响：来自血管内成像的见解。

IF 2.3 4区医学

Current Opinion in Cardiology Pub Date : 2023-11-01 Epub Date: 2023-09-25 DOI: 10.1097/HCO.0000000000001080

Timothy Abrahams, Masashi Fujino, Adam J Nelson, Stephen J Nicholls

{"title":"Impact of PCSK9 inhibitors on coronary atheroma phenotype following myocardial infarction: insights from intravascular imaging.","authors":"Timothy Abrahams, Masashi Fujino, Adam J Nelson, Stephen J Nicholls","doi":"10.1097/HCO.0000000000001080","DOIUrl":"https://doi.org/10.1097/HCO.0000000000001080","url":null,"abstract":"Purpose of review: The aim of this study was to review the impact of combination lipid lowering with statins and proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors on coronary atherosclerosis using serial intravascular imaging.Recent findings: Early studies using intravascular ultrasound established the ability of increasingly intensive lipid lowering to both slow progression and ultimately promote regression of coronary disease. More recent clinical trials that have employed serial imaging with optical coherence tomography have permitted the ability to evaluate the impact of intensive lipid lowering on compositional features associated with plaque vulnerability. In particular, the combination of intensive statin and PCSK9 inhibitor therapy promotes plaque stability in patients following an acute coronary syndrome.Summary: More intensive lipid lowering using the combination of statins and PCSK9 inhibitors promote plaque regression in addition to promoting calcification, fibrous cap thickening and reductions in plaque lipid. These plaque-stabilizing effects underscore the benefits of combination therapy on cardiovascular events and highlight the importance of combination lipid-lowering therapy.","PeriodicalId":55197,"journal":{"name":"Current Opinion in Cardiology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41220742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The plaque hypothesis: understanding mechanisms of plaque progression and destabilization, and implications for clinical management. 斑块假说:了解斑块进展和不稳定的机制，以及对临床管理的影响。

IF 2.3 4区医学

Current Opinion in Cardiology Pub Date : 2023-11-01 Epub Date: 2023-08-28 DOI: 10.1097/HCO.0000000000001077

Mona E Ahmed, Diaa Hakim, Peter H Stone

{"title":"The plaque hypothesis: understanding mechanisms of plaque progression and destabilization, and implications for clinical management.","authors":"Mona E Ahmed, Diaa Hakim, Peter H Stone","doi":"10.1097/HCO.0000000000001077","DOIUrl":"10.1097/HCO.0000000000001077","url":null,"abstract":"Purpose of review: Major adverse cardiac events (MACE) typically arise from nonflow-limiting coronary artery disease and not from flow-limiting obstructions that cause ischemia. This review elaborates the current understanding of the mechanism(s) for plaque development, progression, and destabilization and how identification of these high-risk features can optimally inform clinical management.Recent findings: Advanced invasive and noninvasive coronary imaging and computational postprocessing enhance an understanding of pathobiologic/pathophysiologic features of coronary artery plaques prone to destabilization and MACE. Early investigations of high-risk plaques focused on anatomic and biochemical characteristics (large plaque burden, severe luminal obstruction, thin cap fibroatheroma morphology, and large lipid pool), but more recent studies underscore that additional factors, particularly biomechanical factors [low endothelial shear stress (ESS), high ESS gradient, plaque structural stress, and axial plaque stress], provide the critical incremental stimulus acting on the anatomic substrate to provoke plaque destabilization. These destabilizing features are often located in areas distant from the flow-limiting obstruction or may exist in plaques without any flow limitation. Identification of these high-risk, synergistic plaque features enable identification of plaques prone to destabilize regardless of the presence or absence of a severe obstruction (Plaque Hypothesis).Summary: Local plaque topography, hemodynamic patterns, and internal plaque constituents constitute high-risk features that may be located along the entire course of the coronary plaque, including both flow-limiting and nonflow-limiting regions. For coronary interventions to have optimal clinical impact, it will be critical to direct their application to the plaque area(s) at highest risk.","PeriodicalId":55197,"journal":{"name":"Current Opinion in Cardiology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10958790/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41161445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor co-agonists for cardioprotection, type 2 diabetes and obesity: a review of mechanisms and clinical data. 胰高血糖素样肽-1/葡萄糖依赖性促胰岛素多肽受体共激动剂对心脏保护、2型糖尿病和肥胖的作用：机制和临床数据综述。

IF 2.3 4区医学

Current Opinion in Cardiology Pub Date : 2023-11-01 Epub Date: 2023-08-21 DOI: 10.1097/HCO.0000000000001084

Ronald M Goldenberg, Hwee Teoh, Subodh Verma

{"title":"Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor co-agonists for cardioprotection, type 2 diabetes and obesity: a review of mechanisms and clinical data.","authors":"Ronald M Goldenberg, Hwee Teoh, Subodh Verma","doi":"10.1097/HCO.0000000000001084","DOIUrl":"10.1097/HCO.0000000000001084","url":null,"abstract":"Purpose of review: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are approved for the management of type 2 diabetes (T2D) and obesity, and some are recommended for cardiorenal risk reduction in T2D. To enhance the benefits with GLP-RA mono-agonist therapy, GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor co-agonists are in development to capitalize on the synergism of GLP-1 and GIP agonism. We review the mechanisms of action and clinical data for GLP-1/GIP receptor co-agonists in T2D and obesity and their potential role in cardiovascular protection.Recent findings: Tirzepatide, a first-in-class unimolecular GLP-1/GIP receptor co-agonist, is approved for T2D and is awaiting approval for obesity management. Phase 3 trials in T2D cohorts revealed significant reductions in glycemia and body weight and superiority compared with GLP-1R mono-agonism with semaglutide. Tirzepatide has demonstrated significant body weight reductions in individuals with obesity but not diabetes. It enhances lipid metabolism, reduces blood pressure, and lowers liver fat content. Pooled phase 2/3 data showed cardiovascular safety in T2D while a post hoc analysis suggested tirzepatide slows the decline of kidney function in T2D.Summary: GLP-1/GIP receptor co-agonists are a novel addition to the diabetes and obesity armamentarium. The cardiorenal-metabolic benefits position them as promising multiprong tools for metabolically complex individuals with chronic vascular complications.","PeriodicalId":55197,"journal":{"name":"Current Opinion in Cardiology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41161444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The evolving role of cardiopulmonary exercise testing in ischemic heart disease - state of the art review. 心肺运动试验在缺血性心脏病中的演变作用——最新进展综述。

IF 2 4区医学

Current Opinion in Cardiology Pub Date : 2023-11-01 Epub Date: 2023-09-21 DOI: 10.1097/HCO.0000000000001086

Sundeep Chaudhry, Naresh Kumar, Ross Arena, Subodh Verma

{"title":"The evolving role of cardiopulmonary exercise testing in ischemic heart disease - state of the art review.","authors":"Sundeep Chaudhry, Naresh Kumar, Ross Arena, Subodh Verma","doi":"10.1097/HCO.0000000000001086","DOIUrl":"10.1097/HCO.0000000000001086","url":null,"abstract":"Purpose of review: Cardiopulmonary exercise testing (CPET) is the gold standard for directly assessing cardiorespiratory fitness (CRF) and has a relatively new and evolving role in evaluating atherosclerotic heart disease, particularly in detecting cardiac dysfunction caused by ischemic heart disease. The purpose of this review is to assess the current literature on the link between cardiovascular (CV) risk factors, cardiac dysfunction and CRF assessed by CPET.Recent findings: We summarize the basics of exercise physiology and the key determinants of CRF. Prognostically, several studies have been published relating directly measured CRF by CPET and outcomes allowing for more precise risk assessment. Diagnostically, this review describes in detail what is considered healthy and abnormal cardiac function assessed by CPET. New studies demonstrate that cardiac dysfunction on CPET is a common finding in asymptomatic individuals and is associated with CV risk factors and lower CRF. This review covers how key CPET parameters change as individuals transition from the asymptomatic to the symptomatic stage with progressively decreasing CRF. Finally, a supplement with case studies with long-term longitudinal data demonstrating how CPET can be used in daily clinical decision making is presented.Summary: In summary, CPET is a powerful tool to provide individualized CV risk assessment, monitor the effectiveness of therapeutic interventions, and provide meaningful feedback to help patients guide their path to improve CRF when routinely used in the outpatient setting.","PeriodicalId":55197,"journal":{"name":"Current Opinion in Cardiology","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/62/7e/cocar-38-552.PMC10552845.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10169450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Coronary artery calcium and sudden cardiac death: current evidence and future directions. 冠状动脉钙化与心源性猝死：当前证据和未来方向。

IF 2.3 4区医学

Current Opinion in Cardiology Pub Date : 2023-11-01 Epub Date: 2023-08-24 DOI: 10.1097/HCO.0000000000001081

Alexander C Razavi, Seamus P Whelton, Roger S Blumenthal, Laurence S Sperling, Michael J Blaha, Omar Dzaye

{"title":"Coronary artery calcium and sudden cardiac death: current evidence and future directions.","authors":"Alexander C Razavi, Seamus P Whelton, Roger S Blumenthal, Laurence S Sperling, Michael J Blaha, Omar Dzaye","doi":"10.1097/HCO.0000000000001081","DOIUrl":"10.1097/HCO.0000000000001081","url":null,"abstract":"Purpose of review: To provide a summary of the current evidence and highlight future directions regarding coronary artery calcium (CAC) and risk of sudden cardiac death (SCD).Recent findings: Although up to 80% of all SCD is attributed to coronary heart disease (CHD), the subclinical atherosclerosis markers that help to improve SCD risk prediction are largely unknown. Recent observational data have demonstrated that, after adjustment for traditional risk factors, there is a stepwise higher risk for SCD across increasing CAC burden such that asymptomatic patients without overt atherosclerotic cardiovascular disease (ASCVD) experience a three-fold to five-fold higher SCD risk beginning at CAC at least 100 when compared with CAC = 0. Although the mechanisms underlying increasing CAC and SCD risk have yet to be fully elucidated, risk for myocardial infarction and scar, and/or exercise-induced ischemia may be potential mediators.Summary: High CAC burden is an important risk factor for SCD in asymptomatic middle-aged adults, suggesting that SCD risk stratification can begin in the early stages of CHD via measurement of calcific plaque on noncontrast computed tomography. Despite the clinical inertia for downstream functional cardiac testing after detecting high CAC, comprehensive ASCVD prevention strategies should be the primary focus for SCD risk reduction.","PeriodicalId":55197,"journal":{"name":"Current Opinion in Cardiology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10908356/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10413331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antiplatelet therapy around CABG: the latest evidence. CABG的抗血小板治疗：最新证据。

IF 2 4区医学

Current Opinion in Cardiology Pub Date : 2023-11-01 Epub Date: 2023-09-21 DOI: 10.1097/HCO.0000000000001078

Sigrid Sandner, Björn Redfors, Mario Gaudino

{"title":"Antiplatelet therapy around CABG: the latest evidence.","authors":"Sigrid Sandner, Björn Redfors, Mario Gaudino","doi":"10.1097/HCO.0000000000001078","DOIUrl":"10.1097/HCO.0000000000001078","url":null,"abstract":"Purpose of review: The optimal antiplatelet strategy in patients after coronary artery bypass graft (CABG) surgery is unclear. We review the evidence on the efficacy and safety of DAPT after CABG and discuss potential novel antiplatelet strategies that reduce the risk of bleeding without loss of efficacy.Recent findings: Adding the potent P2Y12 inhibitor ticagrelor to aspirin for 1 year after CABG is associated with a reduction in the risk of vein graft failure, at the expense of an increased risk of clinically important bleeding. Ticagrelor monotherapy is not associated with better efficacy than aspirin alone, but is not associated with increased bleeding risk.Summary: Dual antiplatelet therapy (DAPT) is recommended after acute coronary syndrome events, but aspirin as single antiplatelet therapy remains the cornerstone of antithrombotic therapy in stable ischemic heart disease because of a lack of solid evidence on the benefit of DAPT on clinical outcomes. Shorter duration DAPT, based on the pathophysiology of vein graft failure, may be a promising strategy that requires testing in adequately powered randomized trials.","PeriodicalId":55197,"journal":{"name":"Current Opinion in Cardiology","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c0/4d/cocar-38-484.PMC10552805.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41123846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0